Blue Trust Inc. Acquires 4,185 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Blue Trust Inc. raised its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 40.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 14,619 shares of the company’s stock after purchasing an additional 4,185 shares during the period. Blue Trust Inc.’s holdings in Teva Pharmaceutical Industries were worth $263,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Janney Montgomery Scott LLC boosted its position in shares of Teva Pharmaceutical Industries by 13.6% during the first quarter. Janney Montgomery Scott LLC now owns 1,372,477 shares of the company’s stock valued at $19,366,000 after purchasing an additional 164,614 shares in the last quarter. QRG Capital Management Inc. grew its position in shares of Teva Pharmaceutical Industries by 53.7% in the 1st quarter. QRG Capital Management Inc. now owns 143,747 shares of the company’s stock worth $2,028,000 after buying an additional 50,247 shares during the period. Capital Wealth Planning LLC purchased a new stake in shares of Teva Pharmaceutical Industries in the 1st quarter worth about $2,169,000. SG Americas Securities LLC increased its stake in shares of Teva Pharmaceutical Industries by 12.0% in the 1st quarter. SG Americas Securities LLC now owns 610,407 shares of the company’s stock worth $8,613,000 after acquiring an additional 65,529 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. lifted its position in Teva Pharmaceutical Industries by 30.3% during the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 206,162 shares of the company’s stock valued at $2,909,000 after acquiring an additional 47,954 shares during the period. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on TEVA. Argus upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 target price for the company in a report on Wednesday, July 10th. UBS Group boosted their target price on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Barclays increased their target price on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an “overweight” rating in a research note on Wednesday. StockNews.com raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research report on Monday. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $19.67.

Insider Buying and Selling

In related news, insider Eric A. Hughes sold 24,537 shares of the firm’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $17.25, for a total value of $423,263.25. Following the completion of the transaction, the insider now owns 45,060 shares in the company, valued at $777,285. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.55% of the stock is owned by company insiders.

Teva Pharmaceutical Industries Price Performance

TEVA opened at $18.25 on Friday. The company has a market capitalization of $20.67 billion, a price-to-earnings ratio of -44.50, a PEG ratio of 1.32 and a beta of 0.88. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 2.52. Teva Pharmaceutical Industries Limited has a 12-month low of $8.10 and a 12-month high of $19.08. The business’s fifty day simple moving average is $18.02 and its 200-day simple moving average is $16.73.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings results on Wednesday, July 31st. The company reported $0.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.55 by $0.03. Teva Pharmaceutical Industries had a positive return on equity of 39.66% and a negative net margin of 2.73%. The business had revenue of $4.16 billion for the quarter, compared to the consensus estimate of $3.99 billion. On average, equities research analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.33 earnings per share for the current fiscal year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.